|Issuer:||TARSUS PHARMACEUTICALS, INC. (TARS)|
|Original Submission Date:|
TREVEJO JOSE M.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE, CA
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|RESTRICTED STOCK UNITS||0.0||2023-03-15||deemed execution date||M||7,549 (d)||common stock 7,549||$0.00||22,648||direct|
|f1||the shares were issued pursuant to settlement of vested restricted stock units ("rsus").|
|f2||includes 1,604 shares acquired under the issuer's employee stock purchase plan on december 31, 2022.|
|f3||the sale reported on this form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of rsus. the sale is mandated by the issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.|
|f4||each rsu represents a contingent right to receive one share of the company's common stock.|
|f5||rsu granted on february 1, 2022, under the tarsus pharmaceuticals, inc. 2020 stock plan. 25% of the rsus will vest on march 15th of each of 2023, 2024, 2025, and 2026, subject to the reporting person's continuous service.|